Biologics

MiMedx releases AmnioFix Injectable

MiMedx Group Inc. announced the launch of its newest tissue product, AmnioFix Injectable, at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting in San Francisco.

 According to a company press release, AmnioFix Injectable is an allograft composed of micronized amniotic tissue, which is processed to optimize surgical performance and ease of use. The company’s proprietary Purion process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue, resulting in an injectable tissue that offers a natural ability to reduce inflammation at the injection site and enhance soft tissue healing. AmnioFix has a 5-year shelf-life.

About the author

Josh Sandberg

Josh Sandberg has been an executive search consultant focused exclusively on orthopedic and spine start-ups since 2004. He has had a tremendous impact in helping his clients avoid costly hiring mistakes by his deep industry knowledge and network. In 2010, Josh co-founded Ortho Spine Companies, which is the parent company of Ortho Spine Distributors (OSD), Surg.io and Ortho Sales Partners (OSP). OSD a searchable database that helps ease the frustration of finding orthopedic distributors throughout the country. Surg.io is the ultimate distributor toolkit that offers distributors the tools necessary to build the foundation of a scalable and highly functioning sales organization. OSP is an end-to-end solution that helps companies approach the Global Market in a cost efficient way. Our team has hundreds of years of experience and can help you navigate the many challenges present in bringing new technologies to the market.

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *

Polls

Alphatec Spine sold their OUS business to Globus. What do you expect to be the fate for the rest of Alphatec?

View Results

Loading ... Loading ...

Ortho Kinematics